Biomedical Engineering Reference
In-Depth Information
References
Abraham MR, Henrikson CA, Tung L, et al. Antiarrhythmic Engineering of Skeletal Myoblasts
for Cardiac Transplantation. Circulation Research 2005;97:159-67.
Al-Allaf FA, Coutelle C, Waddington SN, et al. LDLR-Gene therapy for familial hypercholesterolae-
mia: problems, progress, and perspectives. Int Arch Med 2011; doi: 10.1186/1755-7682-3-36.
Athyros VG, Kakafika AI, Tziomalos K, et al. Antisense technology for the prevention or the
treatment of cardiovascular disease: the next blockbuster? Expert Opin Investig Drugs 2008;
17:969-72.
Bell DA, Hooper AJ, Burnett JR. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
Expert Opin Invest Drugs 2011;20:265-272.
Bott-Flugel L, Weig HJ, Knodler M, et al. Gene transfer of the pancaspase inhibitor P35 reduces
myocardial infarct size and improves cardiac function. J Mol Med 2005;83:526-34.
Brinks H, Boucher M, Gao E, et al. Level of G protein-Coupled Receptor Kinase-2 Determines
Myocardial Ischemia/Reperfusion Injury via Pro- and Anti-Apoptotic Mechanisms. Circ Res
2010;107:1140-9.
Cai X, Freedman NJ. New therapeutic possibilities for vein graft disease in the post-edifoligide
era. Future Cardiology 2006;2:493-501.
Chorny M, Polyak B, Alferiev IS, et al. Magnetically driven plasmid DNA delivery with biode-
gradable polymeric nanoparticles. FASEB J 2007;21:2510-9.
Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo
antisense targeting. Cell Metab 2006;3:87-98.
Fishbein I, Stachelek SJ, Connolly JM, et al. Site specific gene delivery in the cardiovascular
system. J Control Release 2005;109:37-48.
Gao MH, Lai NC, Hammond HK. Signal peptide increases the efficacy of angiogenic gene trans-
fer for treatment of myocardial ischemia. Hum Gene Ther 2005;16:1058-64.
Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert
Opin Biol Ther 2008;8:911-22.
Hagikura K, Fukuda N, Yokoyama S, et al. Low invasive angiogenic therapy for myocardial
infarction by retrograde transplantation of mononuclear cells expressing the VEGF gene. Int
J Cardiol 2010;142:56-64.
Ikeda S, Kong SW, Lu J, et al. Altered microRNA expression in human heart disease. Physiol
Genomics 2007;31:367-73.
Jacobs J. Combating cardiovascular disease with angiogenic therapy. Drug Discov Today 2007;
12:1040-5.
Jain KK. Textbook of Gene therapy. Hogrefe, Göttingen, 1998.
Jain KK. RNAi: technologies, markets and companies. Jain PharmaBiotech, Basel, 2011a.
Jain KK. Gene therapy: technologies, markets and companies. Jain PharmaBiotech, Basel, 2011b.
Jones SP, Greer JJ, van Haperen R, et al. Endothelial nitric oxide synthase overexpression attenu-
ates congestive heart failure in mice. PNAS 2003;100:4891-6.
Kastrup J. Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular
growth factor protein therapy? Curr Gene Ther 2003;3:197-206.
Kim SH, Moon HH, Kim HA, et al. Hypoxia-inducible Vascular Endothelial Growth Factor-
engineered Mesenchymal Stem Cells Prevent Myocardial Ischemic Injury. Mol Ther 2011 Jan
18;doi:10.1038/mt.2010.301.
Komamura K, Miyazaki J, Imai E, et al. Hepatocyte growth factor gene therapy for hypertension.
Methods Mol Biol 2008;423:393-404.
Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial
microRNAs expression and angiogenesis. Circ Res 2007;101:59-68.
Li YL, Li YF, Liu D, et al. Gene Transfer of Neuronal Nitric Oxide Synthase to Carotid Body
Reverses Enhanced Chemoreceptor Function in Heart Failure Rabbits. Circ Res 2005;
97:260-267.
Search WWH ::
Custom Search